KYNTRA BIO, INC. [KYNB] - appoints Andrew E. Singer as Director
Effective October 1, 2026, Kyntra Bio, Inc. appointed Andrew E. Singer, MBA, as a Class III director and member of the Audit Committee, succeeding Maykin Ho, Ph.D., who will resign on September 30, 2026.
Why this matters
Kyntra Bio, Inc. is a biopharmaceutical company focused on developing novel therapies for oncology and rare diseases, with products like Roxadustat approved in several countries for treating anemia in chronic kidney disease patients. The company has appointed Andrew E. Singer, MBA, as a Class III director and member of the Audit Committee, effective October 1, 2026, following the resignation of Maykin Ho, Ph.D., on September 30, 2026. Singer brings over 25 years of experience in biotechnology finance and strategy, having previously held senior roles at Credit Suisse and Wells Fargo, and currently serves as CEO of Fika Bio Consulting, Inc.